Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 6, 2014, Pages 484-491

  Gao, Minjie ^a   Gao, Lu ^a   Tao, Yi ^a   Hou, Jun ^a   Yang, Guang ^a   Wu, Xiaosong ^a   Xu, Hongwei ^b   Tompkins, Van S ^b   Han, Ying ^a   Wu, Huiqun ^a   Zhan, Fenghuang ^b   Shi, Jumei ^a  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; Carfilzomib; Jurkat; Reactive oxygen species; Vorinostat

Indexed keywords

CARFILZOMIB; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; OLIGOPEPTIDE; PROTEASOME; REACTIVE OXYGEN METABOLITE; VORINOSTAT;

APOPTOSIS; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; JURKAT CELL LINE; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL;

APOPTOSIS; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; JURKAT CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES;

EID: 84901684160     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu030     Document Type: Article

References (25)

1. Ge J, Liu Y, Li Q, Guo X, Gu L, Ma ZG and Zhu YP. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK. Biomed Environ Sci 2013, 26: 902-911
2. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG and Burger NB, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008, 22: 124-131
3. Armstrong F, Brunet DLGP, Gerby B, Rouyez MC, Calvo J, Fontenay M and Boissel N, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009, 113: 1730-1740
4. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M and Loning L, et al. Risk-Adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008, 111: 4477-4489
5. Huang C, Hu X, Wang L, Lu S, Cheng H, Song X and Wang J, et al. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemother Pharmacol 2012, 70: 801-809
6. Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E and Fisher RI, et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC-And ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther 2012, 11: 1122-1132
7. Mateos MV, Ocio EM and San MJ. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol 2013, 40: 618-633
8. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM and Grandis JR, et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res 2012, 18: 5639-5649
9. Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD and Habtemariam B, et al. U.S. Food and drug administration approval: Carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013, 19: 4559-4563
10. Robert C and Rassool FV. HDAC inhibitors: Roles of DNA damage and repair. Adv Cancer Res 2012, 116: 87-129
11. Licciardi PV, Ververis K, Tang ML, El-Osta A and Karagiannis TC. Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med 2013, 13: 640-647
12. Glass E and Viale PH. Histone deacetylase inhibitors: Novel agents in cancer treatment. Clin J Oncol Nurs 2013, 17: 34-40
13. Hui KF, Lam BH, Ho DN, Tsao SW and Chiang AK. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther 2013, 12: 747-758
14. Jiang Y, Wang Y, Su Z, Yang L, Guo W, Liu W and Zuo J. Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. Mol Med Rep 2010, 3: 613-619
15. Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, Shen ZX and Li JM. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 2011, 90: 917-931
16. Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G and Prada J, et al. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3 K/AKT, and NF-kappaB. Clin Cancer Res 2013, 19: 1445-1457
17. Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P and Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115: 4478-4487
18. Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI and Friedberg JW, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 2011, 10: 1686-1697
19. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M and Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110: 267-277. (Pubitemid 47026844)
20. Pei XY, Dai Y and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10: 3839-3852. (Pubitemid 38697620)
21. Repicky A, Jantova S and Cipak L. Apoptosis induced by 2-Acetyl-3-(6-methoxybenzothiazo)-2-yl-Amino-Acrylonitrile in human leukemia cells involves ROS-mitochondrial mediated death signaling and activation of p38 MAPK. Cancer Lett 2009, 277: 55-63
22. Yu C, Rahmani M, Conrad D, Subler M, Dent P and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571. Blood 2003, 102: 3765-3774. (Pubitemid 37409399)
23. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L and Prachand S, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 2009, 15: 3354-3365
24. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL and Janin A, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23: 1507-1514
25. Matthews GM, Newbold A and Johnstone RW. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 2012, 116: 165-197